Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Vbi Vaccines Inc CS (VBIV)
Vbi Vaccines Inc CS (VBIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,534
  • Shares Outstanding, K 8,608
  • Annual Sales, $ 1,080 K
  • Annual Income, $ -113,300 K
  • 60-Month Beta 1.83
  • Price/Sales 22.67
  • Price/Cash Flow N/A
  • Price/Book 0.54
Trade VBIV with:

Options Overview Details

View History
  • Implied Volatility 113.85% ( -14.80%)
  • Historical Volatility 94.64%
  • IV Percentile 30%
  • IV Rank 7.51%
  • IV High 1,414.67% on 02/16/23
  • IV Low 8.26% on 07/13/22
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 11,656
  • Open Int (30-Day) 11,652

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -2.13
  • Number of Estimates 2
  • High Estimate -2.10
  • Low Estimate -2.16
  • Prior Year -5.41
  • Growth Rate Est. (year over year) +60.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.56 +11.33%
on 05/25/23
3.33 -14.41%
on 05/23/23
-0.04 (-1.38%)
since 05/02/23
3-Month
2.35 +21.28%
on 04/26/23
15.05 -81.06%
on 03/06/23
-11.06 (-79.51%)
since 03/02/23
52-Week
2.35 +21.28%
on 04/26/23
40.50 -92.96%
on 08/16/22
-25.16 (-89.83%)
since 06/02/22

Most Recent Stories

More News
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Absci Corporation (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABSI : 1.8800 (+2.17%)
VBIV : 2.85 (unch)
VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBIV : 2.85 (unch)
MIRM : 26.33 (+0.84%)
VBI Vaccines Appoints Vaughn Himes to Board of Directors

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief...

VBIV : 2.85 (unch)
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

CRSP : 65.00 (+0.74%)
VBIV : 2.85 (unch)
CERT : 21.70 (+1.83%)
EQRX : 1.8300 (+0.55%)
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced plans to focus the Company’s efforts...

VBIV : 2.85 (unch)
Calling All Quality Control: Get Rid of These 3 Biotech Stocks ASAP!

High-interest rates are expected to impact the growth of the biotech industry. Therefore, fundamentally weak biotech stocks Bionano Genomics (BNGO), VBI Vaccines (VBIV), and 180 Life Sciences (ATNF) might...

ATNF : 1.1900 (unch)
BNGO : 0.7940 (+8.44%)
VBIV : 2.85 (unch)
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 27.29 (+1.49%)
VBIV : 2.85 (unch)
ANTX : 6.41 (+7.37%)
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

VBIV : 2.85 (unch)
USAQ : 0.1500 (+1.35%)
VBI Vaccines Reports Full Year 2022 Financial Results

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial...

VBIV : 2.85 (unch)
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 8.54% and 24.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

RYTM : 17.85 (+3.96%)
VBIV : 2.85 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus...

See More

Key Turning Points

3rd Resistance Point 3.24
2nd Resistance Point 3.11
1st Resistance Point 2.98
Last Price 2.85
1st Support Level 2.72
2nd Support Level 2.59
3rd Support Level 2.46

See More

52-Week High 40.50
Fibonacci 61.8% 25.93
Fibonacci 50% 21.42
Fibonacci 38.2% 16.92
Last Price 2.85
52-Week Low 2.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar